Discontinued drugs in 2005: Anti-infectives

Expert Opinion on Investigational Drugs

Volumn 16, Issue 1, 2007, Pages 1-10

  Georgopapadakou, Nafsika ^a  

^a METHYLGENE INC   (Canada)

Author keywords

Alovudine; Anthrax vaccine; Antivirals; Aplaviroc; Ciluprevir; Dermofural ; ISIS 14803; JTK 003; R803; Topical econazole; Xcellerate

Indexed keywords

3' FLUOROTHYMIDINE; ANTHRAX VACCINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFECTIVE AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; APLAVIROC; BACTERIAL ANTIGEN; BACTERIAL PROTECTIVE ANTIGEN; BACTERIAL PROTEIN; CILUPREVIR; DERMOFURAL; DNA VACCINE; E 913; ECONAIL; ECONAZOLE; ENFUVIRTIDE; FURAN DERIVATIVE; FURAPROFEN; GENTAMICIN; HCV 086; INDINAVIR; ISIS 14803; JTK 003; KETOCONAZOLE; LETHAL FACTOR PROTEIN; NEVIRAPINE; NUCLEOTIDYLTRANSFERASE INHIBITOR; PLACEBO; STAVUDINE; UNINDEXED DRUG; VINYLFURAN G1; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHRAX; ANTIMICROBIAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; BACTERIAL SKIN DISEASE; BILIRUBIN BLOOD LEVEL; CANCER IMMUNOTHERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRYOGLOBULINEMIA; DERMATOMYCOSIS; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESEARCH; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; GLOMERULONEPHRITIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; MONOTHERAPY; MYCOSIS; NONHUMAN; ONYCHOMYCOSIS; QT PROLONGATION; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TOENAIL ONYCHOMYCOSIS; UNSPECIFIED SIDE EFFECT; VACCINATION;

ANIMALS; ANTI-INFECTIVE AGENTS; COMMUNICABLE DISEASES; DRUG AND NARCOTIC CONTROL; HUMANS;

EID: 33845687669     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.1.1     Document Type: Article

References (51)

1. TENOVER FC: Mechanisms of antimicrobial resistance in bacteria. Am. J Infect. Control. (2006) 34(5 Suppl. 1):S3-S10 (Discussion S64-573).
2. LODE H: Management of serious nosocomial bacterial infections: do current therapeutic options meet the need? Clin. Microbiol. Infect. (2005) 11(10):778-787.
3. DONSKEY CJ: Antibiotic regimens and intestinal colonization with antibiotic-resistant Gram-negative bacilli. Clin. Infect. Dis. (2006) 43(Suppl. 2):S62-S69.
4. BONOMO RA, SZABO D: Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin. Infect. Dis. (2006) 43(Suppl. 2):S49-S56.
5. RICE LB: Antimicrobial resistance in Gram-positive bacteria. Am. J. Infect. Control (2006) 34(5 Suppl. 1):S11-S19 (Discussion S64-S73).
6. CHAMBERS HF: Community-associated MRSA-resistance and virulence converge. N. Engl. J. Med. (2005) 352(14):1485-1487.
7. KAUFFMAN CA: Fungal infections. Proc. Am. Thorac. Soc. (2006) 3(1) 35-40.
8. NUCCI M, MARR KA: Emerging fungal diseases. Clin. Infect. Dis. (2005) 41(4):521-526.
9. PFALLER MA, DIEKEMA DJ: Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J. Clin. Microbiol. (2004) 42(10):4419-4431.
10. CHARLES M, PAPE JW: Tuberculosis and HIV: implications in the developing world. Curr. HIV/AIDS Rep. (2006) 3(3):139-144.
11. JOHNSON R, STREICHER EM, LOUW GE, WARREN RM, VAN HELDEN PD, VICTOR TC: Drug resistance in Mycobacterium tuberculosis. Curr. Issues Mol. Biol (2006) 8(2):97-111.
12. POL S, MALLET VO: Improving anti-hepatitis C virus therapy. Expert Opin. Biol Ther. (2006) 6(9):923-933.
13. ANDERSSON K, CHUNG RT: Hepatitis C virus in the HIV-infected patient. Clin. Liver Dis. (2006) 10(2):303-320 (viii).
14. WEIS N, LINDHARDT BO, KRONBORG G et al.: Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Clin. Infect. Dis. (2006) 42(10):1481-1487.
15. CHUNG RT: Hepatitis C and B viruses: the new opportunists in HIV infection. Top. HIV Med. (2006) 14(2):78-83.
16. DAILY JP: Antimalarial drug therapy: the role of parasite biology and drug resistance. J. Clin. Pharmacol. (2006) 46(12):1487-1497.
17. BLOLAND PB, BARAT LM: Drug resistance among malaria and other parasites. Infect. Dis. Clin. North Am. (1997) 11(4):969-987.
18. TROUILLER P, TORREELE E, OLLIARO P et al.: Drugs for neglected diseases: a failure of the market and a public health failure? Trop. Med. Int. Health (2001) 6(11):945-951.
19. TALBOT GH, BRADLEY J, EDWARDS JE Jr, GILBERT D, SCHELD M, BARTLETT JG: Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. (2006) 42(5):657-668.
20. NORRBY SR, NORD CE, FINCH R; EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES: Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect. Dis. (2005) 5(2):115-119.
21. POWERS JH: Development of drugs for antimicrobial-resistant pathogens. Curr. Opin. Infect. Dis. (2003) 16(6):547-551.
22. WATERS L, NELSON M: New therapeutic options for hepatitis C. Curr. Opin. Infect. Dis. (2006) 19(6):615-622.
23. REED C, DAAR ES: Novel antiretroviral agents in HIV therapy. Curr. Infect. Dis. Rep. (2006) 8(6):489-496.
24. HARTFORD CG, PETCHEL KS, MICKAIL H et al.: Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines. Drug Saf. (2006) 29(8):657-673.
25. SENNEVILLE E, LEGOUT L, VALETTE M et al.: Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J. Antimicrob. Chemother. (2004) 54(4):798-802.
26. KASBEKAR N, ACHARYA PS: Telithromycin: the first ketolide for the treatment of respiratory infections. Am. J. Health Syst. Pharm. (2005) 62(9):905-916.
27. GUETTOUCHE T, HNATYSZYN HJ: Chronic hepatitis B and viral genotype: the clinical significance of determining HBV genotypes. Antivir. Ther. (2005) 10(5):593-604.
28. KAPOOR A, JONES M, SHAFER RW, RHEE SY, KAZANJIAN P, DELWART EL: Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay. J. Virol. (2004) 78(13):7112-7123.
29. SNOUNOU G, BECK HP: The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Parasitol. Today (1998) 14(11):462-467.
30. DANEMAN N, McGEER A, GREEN K, LOW DE: Toronto Invasive Bacterial Diseases Network. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin. Infect. Dis. (2006) 43(4):432-438.
31. 7th International Conference on AIDS, Florence, Italy (1991):WA1016-8 (Abstract).
32. 7th International Conference on AIDS, Florence, Italy (1991):WA1020 (Abstract).
33. 7th International Conference on AIDS, Florence, Italy (1991):WA1034 (Abstract).
34. 7th International Conference on AIDS, Florence, Italy (1991):WA1041 (Abstract).
35. 7th International Conference on AIDS, Florence, Italy (1991):WB2114 (Abstract).
36. 7th International Conference on AIDS, Florence, Italy (1991):ThA21 (Abstract).
37. 8th International Conference on AIDS, Amsterdam (1992):WeB1012 (Abstract).
38. 8th International Conference on AIDS, Amsterdam (1992):PoB3025 (Abstract).
39. 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2003).
40. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA (2004):H-211 (Abstract).
41. 15th International AIDS Conference, Bangkok, China (2004):WeOrA1231 (Abstract).
42. 12th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2005):543 (Abstract).
43. 12th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2005):664 (Abstract).
44. 12th Conference on Retroviruses and Opportunistic Infectious Diseases, Boston, USA (2005):664 (Abstract).
45. 53rd Meeting of the American Association for the Study of Liver Diseases, Boston, USA (2002):464 (Abstract).
46. 53rd Meeting of the American Association for the Study of Liver Diseases, Boston, USA (2002):800 (Abstract).
47. 53rd Meeting of the American Association for the Study of Liver Diseases, Boston, USA (2003).
48. TAN S-L, ARNIM P, Y SHI, NAHUM S: Hepatitis C therapeutics: current status and emerging strategies. Nat. Rev. Drug Discov. (2002) 1:867.
49. 18th International Symposium on Medicinal Chemistry, Copenhagen, Denmark (2004):L29 (Abstract).
50. 2nd International Conference on Viral Hepatitis, Hawaii, USA (1998): P35 (Abstract).
51. American Association for the Study of Liver Diseases, Boston, USA (2003):312(Abstract).